Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the relevance of determining EGFR-variant-III status in glioblastomas?

Nature Clinical Practice Oncology volume 5, pages 188–189 (2008)Cite this article

boxed-textPelloski CE et al. (2007) Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25: 2288–2294

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Omuro AM et al. (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6: 1909–1919

    Article  CAS  Google Scholar 

  2. Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024

    Article  CAS  Google Scholar 

  3. Shinojima N et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962–6970

    CAS  PubMed  Google Scholar 

  4. Liu L et al. (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83: 917–926

    Article  CAS  Google Scholar 

  5. Pelloski CE et al. (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935–3941

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Groupe Hospitalier Pitié-Salpétrière, Division de Neurologie, Mazarin 47, Boulevard de l'Hopital, 75661 Paris, France antonio.omuro@psl.aphp.fr

Authors and Affiliations

  1. AMP Omuro is an Attending Physician at Hôpital Pitié-Salpétrière, Paris, France.,

    Antonio MP Omuro

Authors
  1. Antonio MP Omuro
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Omuro, A. What is the relevance of determining EGFR-variant-III status in glioblastomas?. Nat Rev Clin Oncol 5, 188–189 (2008). https://doi.org/10.1038/ncponc1074

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1074

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing